Tryp Therapeutics - Addressing chronic pain with pioneering new treatments!

By Kirsteen Mackay


In this article

  • Loading...
  • Want to see what you should be buying? Check out our top picks.

Psychedelic stock Tryp Therapeutics is pursuing vast market potential by targeting chronic pain...

Psychedelic drug development beyond mental health.


Psychedelic stock Tryp Therapeutics is pursuing vast market potential by targeting chronic pain and other indications rather than mental health.

Indeed, the pioneering psychedelic company is developing treatments for some of the world’s most crippling pain and eating disorders. These include fibromyalgia, phantom limb pain, binge eating disorder and hypothalamic obesity and complex regional pain syndrome (CRPS).

Realizing the full potential of psychedelics

It may be surprising to learn that debilitating pain can be treated with psychedelics. The reason being, many types of chronic pain originate in the brain, so psychedelics can potentially help rewire the brain to address the source of the pain rather than just treating the symptoms.

Tryp Therapeutics is on a mission to develop psilocybin-based treatments for chronic pain and eating disorders. These conditions are all too common, and those suffering are desperately underserved.

Can Tryp Therapeutics help alleviate fibromyalgia?

Fibromyalgia is a painful and draining illness. It’s believed to affect as many as 1 in 20 people globally, and more than 4 million people in the U.S. have been diagnosed with the disease. That’s an enormous addressable market desperately seeking pain relief.

Nearly 30% of fibromyalgia patients are currently prescribed opioids to manage their pain.

Apart from the risk of overdose and addiction, prolonged use can cultivate a self-destructive spiral that ruins multiple lives.

Therefore, anything that can ease pain and reduce suffering is greatly sought after.

And this is where psilocybin stands to shine.

Recreating neural connections and identifying pain triggers can be transformative in managing the root of the pain and other symptoms of fibromyalgia. And psilocybin has outstanding potential to do just that.

But it’s not just fibromyalgia sufferers that stand to benefit.

For an inside look at this rare opportunity – DOWNLOAD the Tryp Therapeutics investor deck now!

Switching off the phantom limb pain trigger

Despite their heroic efforts, many US military veterans return battle-scarred and limbless, only to suffer such horrors as PTSD and phantom limb pain.

Of course, it’s not just veterans suffering. Phantom limb pain affects over a million people in the US.

This is a shocking number to be left in limbo. Indeed, over 60% of patients who have lost a limb suffer from this distressing condition.

While other psychedelic research studies are already addressing PTSD, Tryp Therapeutics focuses on how psilocybin can relieve phantom limb pain.

By pioneering patented formulations for synthetic psilocybin, it hopes to tackle this horrifying problem head-on.

But that’s not all.

Eating disorders lead to depression

As the world has become increasingly body-conscious, eating disorders are on the rise. Another alarming statistic shows close to 3.5% of females and 2% of males suffer from a binge eating disorder throughout their lives.

The world’s obesity problem is getting worse, and weight loss solutions are more prevalent than ever. But few actually work, and this cyclical process of binge eating puts terrible pressure on the body and mind.

Tryp Therapeutics hopes to solve the decades-old problem of binge eating while patenting its targeted formulations and pioneering new ways to manufacture the drugs along the way.

As well as binge eating, Tryp Therapeutics is focusing on a much rarer eating disorder known as hypothalamic obesity. There are less than 10k diagnosed cases in the US, but these individuals are left to suffer in silence with no approved treatments.

Combatting the ‘suicide disease’

Finally, Tryp Therapeutics is also targeting complex regional pain syndrome (CRPS).

Little known but excruciatingly painful, CRPS affects nearly 100k individuals in the US. Indeed, CRPS can be one of the most painful of all medical disorders.

Devastatingly nicknamed the ‘suicide disease,’ CRPS desperately needs better treatment options.

CRPS is caused by persistent pain that the brain has learned from a prior injury that has already fully healed. The brain gets stuck in a pain loop that can seem to have no end.

Psychedelic therapies can alter the mind and the connections within the brain, potentially offering CRPS sufferers a chance at pain relief.

It is utterly cruel to let people suffer in such unbearable pain that suicide can seem for many to be their only way out. Surely an opportunity to alleviate such pain should be explored?

Tryp Therapeutics thinks so, and that’s why it’s targeting the disease while pursuing global patents at every opportunity.

The power of psychedelics beyond mental health is largely untapped, and a broader universe of use cases are opening up. That’s why Tryp Therapeutics is tapping into this underexplored area of chronic pain and other diseases.

Tryp Therapeutics is playing in the big leagues


Tryp Therapeutics has already filed a provisional patent application and has several more in the pipeline.

This is tremendously impressive because, despite its size, it’s playing in the big leagues with peers such as Compass Pathways and MindMed.

Only a handful of highly-regarded players in the psychedelics field have already kicked-off their Phase 2 clinical trials. Compass Pathways is finalizing a Phase 2b study for treatment-resistant depression. While non-profit organization MAPS has completed a Phase 3 study for PTSD.

Their success paves the way for others in the space. This is where Tryp Therapeutics shows a distinct advantage because it can go straight to Phase 2 thanks to the extensive amount of safety data already produced on psilocybin.

Furthermore, the risk of failure decreases, and value increases with each major milestone achieved along the clinical path.

And as Tryp Therapeutics leads the next generation of clinical research into psychedelic drug development focused on pain relief, it presents a significant upside opportunity for shareholders.

There are three significant milestones in clinical development, and each phase takes considerable time and effort:

  1. Submitting an Investigational New Drug (IND) application to the FDA

  2. Enrolling the first patient in the trial

  3. Trial results

Tryp Therapeutics already has one IND submission under its belt, with another right around the corner. This is a process that requires hundreds of collaborative, scientific effort and is a significant milestone to pass.

The recent filing of an IND for its upcoming Phase 2a study with the University of Florida is among several academic collaborations that Tryp Therapeutics will be announcing soon. Tryp Therapeutics will also be submitting an IND for its Phase 2a clinical trial for fibromyalgia with the University of Michigan in 4Q 2021.

Meanwhile, for its first Phase 2a trial, Tryp Therapeutics has partnered with Jennifer Miller, M.D., an expert in eating disorders. The company expects to enroll its first patients in the study before the end of the year.

Tryp Therapeutics is progressing with two formulations. One is a standard oral form of synthetic psilocybin, while the other is a psilocybin-based product that offers an improved way to administer the drug. The goal is to improve the patient experience

DOWNLOAD the investor deck for more information on this incredible opportunity NOW!

Impressive scientific support

Robin Carhart-Harris, Ph.D. is Chairman of Tryp Therapeutics’ Scientific Advisory Board. This is an extremely impressive individual to back the team.

Carhart-Harris is a psychologist, neuroscientist, and pioneer of psychedelic therapies. In fact, he has published more papers on psilocybin than anyone else in the world.

He trained under the mentorship of Professor David Nutt and recently featured in a BBC documentary called The Psychedelic Drug Trial. Furthermore, he’s Head of the Centre for Psychedelic Research, Division of Brain Sciences at Imperial College London, and Director of the Neuroscape Psychedelic Division at the University of California, San Francisco.

Earlier this year, Dr. Robin Carhart-Harris said:


Several impressive figures accompany Carhart-Harris on the Scientific Advisory Board.

Daniel Clauw, M.D. is Scientific Advisor to Tryp Therapeutics. He’s a world-leading expert in fibromyalgia and other nociplastic pain indications. Dr. Clauw is also Director of the Chronic Pain & Fatigue Research Center and Professor of Anesthesiology, Medicine, and Psychiatry at the University of Michigan Medical School.

Psychedelic stocks are hot right now!

Psychedelic drug development remains among the hottest sectors of the biotech industry.

There are several reasons to be excited about investing in Tryp Therapeutics Therapeutics. It’s one of very few psychedelic drug development companies that have submitted IND’s for Phase 2 clinical trials.

Moreover, with two of these starting soon and another two early next year, it will be as advanced in the clinic as its much larger peers.

This represents a significant upside opportunity to Tryp Therapeutics’ share price. Plus, a unique and undervalued prospect for investors.



This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Tryp Therapeutics to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of one hundred and sixty-six thousand US dollars to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.


Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.


This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.


Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.

This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views.


The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.


This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.


By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.


By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here and acknowledge that you have reviewed the Disclaimer found here If you do not agree to the Terms of Use, please contact to discontinue receiving future communications.


All trademarks used in this communication are the property of their respective trademark holders. Other than, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than

AUTHORS: VALUETHEMARKETS and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.

ValueTheMarkets do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. ValueTheMarkets have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of, has been paid for the production of this piece by the company or companies mentioned above.


In this article:

Author: Kirsteen Mackay

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Kirsteen Mackay currently holds a position or positions in the stock(s) and/or financial instrument(s) mentioned in the above article.

Kirsteen Mackay has not been paid to produce this piece by the company or companies mentioned above.

Digitonic Ltd, the owner of, does not hold a position or positions in the stock(s) and/or financial instrument(s) mentioned in the above article.

Digitonic Ltd, the owner of, has not been paid for the production of this piece by the company or companies mentioned above.

Sign up for Investing Intel Newsletter